Does OSIMERTINIB Cause Hepatic lesion? 7 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 7 reports of Hepatic lesion have been filed in association with OSIMERTINIB (TAGRISSO). This represents 0.0% of all adverse event reports for OSIMERTINIB.
7
Reports of Hepatic lesion with OSIMERTINIB
0.0%
of all OSIMERTINIB reports
2
Deaths
3
Hospitalizations
How Dangerous Is Hepatic lesion From OSIMERTINIB?
Of the 7 reports, 2 (28.6%) resulted in death, 3 (42.9%) required hospitalization, and 1 (14.3%) were considered life-threatening.
Is Hepatic lesion Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for OSIMERTINIB. However, 7 reports have been filed with the FAERS database.
What Other Side Effects Does OSIMERTINIB Cause?
Death (10,423)
Malignant neoplasm progression (2,920)
Diarrhoea (1,408)
Drug resistance (1,026)
Fatigue (819)
Rash (772)
Decreased appetite (706)
Drug ineffective (627)
Dyspnoea (621)
Nausea (610)
What Other Drugs Cause Hepatic lesion?
OCTREOTIDE (296)
EVEROLIMUS (171)
RIBOCICLIB (144)
LETROZOLE (139)
CAPECITABINE (124)
ADALIMUMAB (123)
METHOTREXATE (108)
FULVESTRANT (107)
PALBOCICLIB (104)
CYCLOPHOSPHAMIDE (101)
Which OSIMERTINIB Alternatives Have Lower Hepatic lesion Risk?
OSIMERTINIB vs OSPEMIFENE
OSIMERTINIB vs OSPHENA
OSIMERTINIB vs OVINE DIGOXIN IMMUNE FAB
OSIMERTINIB vs OXACILLIN
OSIMERTINIB vs OXALIPLATIN